B007 for treating pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pemphigus (a rare blistering skin condition).
- You have either been newly diagnosed or are having a flare-up (relapse).
- You have not had pemphigus for more than 4 years since your first diagnosis.
- You are not allergic to antibody-based medications (like biologics).
- You are not pregnant, breastfeeding, or planning pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CM313 for people with moderate to severe pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if CM313 can help reduce these blisters and improve quality of life.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
This study tests an experimental drug called HB0034 for people with a sudden, severe flare of generalized pustular psoriasis (GPP). It aims to see if the drug can safely clear the pustules and improve symptoms.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
Hear when a new Pemphigus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.